Pull the syringe to:
(0.100ml)
Concentration: 5.00 mg/ml
Doses per vial: 30
This calculator is provided as a reference tool for research purposes only. Always follow your institution’s safety protocols when handling research compounds.
Retatrutide 10mg is a synthetic research peptide studied in relation to triple incretin pathway research, GIP receptor signalling, GLP-1 receptor signalling, glucagon receptor signalling, metabolic pathway models and endocrine research.
Retatrutide is also known as LY3437943. Research literature describes retatrutide as a triple hormone receptor agonist targeting the GIP, GLP-1 and glucagon receptors. A phase 2 clinical trial published in the New England Journal of Medicine studied retatrutide in people with obesity, but that clinical context should not be used as a product claim for research-use vials.
This product is supplied for laboratory research use only. It is not a medicine, supplement, weight loss product, fat loss product, appetite product, diabetes product, metabolic treatment, body transformation product or injectable product for human use.
| Product Detail | Information |
|---|---|
| Product name | Retatrutide |
| Common research name | LY3437943 |
| Size | 10mg |
| Product type | Research peptide |
| Research category | Metabolic Research / Incretin Research |
| Common research interest | GIP, GLP-1 and glucagon receptor pathway research |
| Receptor profile | Triple GIP / GLP-1 / glucagon receptor agonist research |
| Form | Lyophilised powder |
| Intended use | Laboratory research only |
| Human use | Not for human consumption, administration, weight loss, fat loss, diabetes management or injection |
| Documentation | Certificate of Analysis should be checked before use |
| Component | Research Class | General Research Role |
| Retatrutide | Synthetic peptide research compound | Studied in triple incretin and metabolic receptor pathway research |
| LY3437943 | Development code | Commonly used in clinical and preclinical literature |
| GIP receptor activity | Incretin pathway research | Studied in glucose, insulin and metabolic signalling models |
| GLP-1 receptor activity | Incretin pathway research | Studied in appetite, glucose and metabolic pathway models |
| Glucagon receptor activity | Metabolic pathway research | Studied in energy expenditure, liver metabolism and glucagon pathway models |
| Peptide structure | Engineered peptide analogue | Requires CoA confirmation for sequence, identity and purity |
| Lyophilised peptide preparation | Freeze-dried peptide format | Supports stability before reconstitution when stored correctly |
Product identity, sequence, purity, salt form, counter-ion, assay result and batch information should always be confirmed through supplier documentation and the Certificate of Analysis. Researchers should not rely on product name alone when confirming peptide identity.
Retatrutide is studied as a triple agonist research peptide across the GIP, GLP-1 and glucagon receptor pathways. This makes it different from single GLP-1 receptor agonist research compounds and dual GIP/GLP-1 pathway products.
In research literature, retatrutide is discussed as a triple hormone receptor agonist. Its pathway profile is commonly used to examine how simultaneous GIP receptor, GLP-1 receptor and glucagon receptor signalling may influence metabolic pathway models.
This should be understood as research context only. It should not be used as a claim that a Retatrutide 10mg research vial is approved, safe or effective for weight loss, obesity, diabetes, appetite control, body transformation or human treatment.
| Research Area | Retatrutide |
| Main research category | Triple incretin and metabolic receptor research |
| Common development name | LY3437943 |
| Receptor pathways | GIP receptor, GLP-1 receptor and glucagon receptor |
| GLP-1 pathway interest | Glucose, appetite and incretin pathway research |
| GIP pathway interest | Insulin, incretin and metabolic signalling research |
| Glucagon pathway interest | Energy expenditure, hepatic metabolism and glucagon signalling research |
| Clinical research status | Investigational clinical research context, not an approved general-use product |
| Australian safety context | Unapproved retatrutide-labelled products have been linked to liver injury alerts |
| Product limitation | Research use only, not approved for human use |
| Feature | Retatrutide | Tirzepatide |
| Research class | Triple receptor agonist research peptide | Dual receptor agonist medicine/research peptide context |
| Main receptor pathways | GIP, GLP-1 and glucagon receptors | GIP and GLP-1 receptors |
| Glucagon receptor activity | Included in research profile | Not part of the dual GIP/GLP-1 profile |
| Common research interest | Triple incretin and metabolic pathway research | Dual incretin pathway research |
| Common SEO risk | Being marketed as stronger weight loss or fat loss | Being marketed as weight loss or diabetes treatment |
| Safer positioning | Triple receptor metabolic pathway research | Dual GIP/GLP-1 pathway research |
| Human-use claim | Not appropriate for research-use products | Only relevant to approved medicines where applicable |
| Feature | Retatrutide | Semaglutide |
| Research class | Triple GIP / GLP-1 / glucagon receptor agonist research peptide | GLP-1 receptor agonist medicine/research context |
| Main pathway | GIP, GLP-1 and glucagon receptors | GLP-1 receptor |
| Research positioning | Triple incretin pathway research | GLP-1 pathway research |
| Common online claim risk | Weight loss, fat loss and body transformation | Weight loss and diabetes treatment claims |
| Safer positioning | Metabolic receptor pathway research | GLP-1 receptor pathway research |
| Human-use claim | Not appropriate for research-use products | Only relevant to approved medicines where applicable |
| Feature | Retatrutide | Cagrilintide |
| Research class | Triple incretin receptor agonist research peptide | Amylin analogue research peptide |
| Main pathway | GIP, GLP-1 and glucagon receptor pathways | Amylin and calcitonin receptor family pathway research |
| Common research overlap | Metabolic, appetite and body-weight pathway models | Appetite, satiety and metabolic pathway models |
| Product positioning | Triple receptor metabolic pathway research | Amylin analogue pathway research |
| Common SEO risk | Weight loss and fat loss claims | Appetite suppression and weight loss claims |
| Human-use claim | Not appropriate | Not appropriate |
| Strength | Product Page Positioning |
| Retatrutide 10mg | Lower-strength research vial for protocol-specific concentration planning |
| Retatrutide 15mg | Mid-strength research vial for metabolic pathway research |
| Retatrutide 20mg | Higher-strength research vial for larger protocol-specific concentration planning |
| Retatrutide 30mg | Larger research amount requiring clear strength-specific labelling |
| Retatrutide 60mg | High-strength research amount requiring extra care around concentration planning and compliance wording |
Retatrutide strengths should be treated as product variants, not duplicate product pages. Each strength should have a unique title, meta description, slug, concentration table and internal links to reduce SEO cannibalisation.
Retatrutide should not be promoted as having proven benefits for the human body when sold as a research-use product. It should not be positioned as a weight loss product, obesity product, fat loss peptide, appetite suppressant, diabetes treatment, metabolic treatment, insulin sensitivity product, body transformation product, anti-ageing product, wellness product or injectable product.
For SEO and compliance, it is safer to discuss research pathways rather than direct human benefits. Retatrutide content should focus on GIP receptor research, GLP-1 receptor research, glucagon receptor research, metabolic pathway models and laboratory research contexts.
The TGA has stated that unapproved peptide products have not been assessed for safety, quality or effectiveness, and specifically lists retatrutide among examples of unapproved peptide products raising regulatory and public health risks.
| Common Online Claim | Safer Research-Use Wording |
| Weight loss | Studied in metabolic receptor pathway research models |
| Fat loss | Better framed as metabolic pathway and energy-balance research |
| Appetite suppression | Better framed as GLP-1, GIP and glucagon receptor pathway research |
| Obesity treatment | Not an approved or appropriate product claim |
| Diabetes management | Not an approved or appropriate product claim |
| Insulin sensitivity | Better framed as glucose metabolism pathway research |
| Body transformation | Not suitable for research-use product positioning |
| Stronger than Ozempic | Avoid comparative consumer claims and use receptor-pathway wording only |
| Stronger than Tirzepatide | Avoid consumer comparison and use triple-receptor research wording only |
Retatrutide 10mg is not intended to diagnose, treat, cure or prevent any disease. It is not supplied for weight loss, fat loss, appetite control, obesity, diabetes, insulin resistance, metabolic syndrome, body transformation, anti-ageing, bodybuilding, wellness, cosmetic use, injection or therapeutic use.
All information on this page is provided for laboratory research and product handling context only.
There is no universal recommended dilution for Retatrutide 10mg. Dilution depends on the research protocol, required working concentration, assay design, solvent compatibility, salt form, storage method and validated laboratory procedure.
For research concentration planning only, the basic formula is:
Total peptide amount divided by diluent volume equals final concentration.
| Diluent Added to 10mg Vial | Final Concentration |
| 1mL | 10mg/mL |
| 2mL | 5mg/mL |
| 2.5mL | 4mg/mL |
| 4mL | 2.5mg/mL |
| 5mL | 2mg/mL |
| 10mL | 1mg/mL |
| 20mL | 0.5mg/mL |
These are research concentration examples only. They are not human dosing instructions and must not be used to calculate injection quantities, treatment quantities, dose escalation or administration schedules.
Before handling Retatrutide 10mg in a laboratory setting, make sure all materials, documentation and clean handling conditions are prepared.
| Item | Purpose |
| Product vial | Contains lyophilised Retatrutide peptide |
| Certificate of Analysis | Confirms batch-level testing information |
| Sequence or identity confirmation | Helps confirm the product is Retatrutide / LY3437943 |
| Suitable research-grade diluent | Used to prepare a working research solution |
| Sterile lab consumables | Helps reduce contamination risk |
| Personal protective equipment | Gloves, lab coat and eye protection |
| Alcohol wipes or approved disinfectant | Used for surface and vial-top preparation |
| Laboratory labels | Records concentration, date, batch and handler details |
| Cold storage access | Supports correct storage after preparation |
| Disposal container | Used for compliant laboratory waste disposal |
The following is a general laboratory handling framework only. Always follow the product Certificate of Analysis, supplier documentation, SDS, institutional procedures and validated research protocol.
Check the product label, batch number, Certificate of Analysis, peptide identity and storage requirements before handling the vial.
Use a clean laboratory workspace. Wear appropriate PPE and disinfect the bench surface, vial top and any required equipment.
If the vial has been stored cold, allow it to equilibrate according to laboratory procedure before opening or reconstitution. Avoid condensation entering the vial.
Add the selected research-grade diluent slowly down the inside wall of the vial. Avoid forceful spraying directly onto the lyophilised powder.
Gently swirl or roll the vial until the powder is dissolved. Avoid aggressive shaking, unnecessary vortexing or foaming unless a validated protocol specifically allows it.
Check the solution for cloudiness, visible particles, unusual colour changes or undissolved material. If anything appears abnormal, quarantine the vial and check supplier documentation.
Label the vial or aliquots with the product name, concentration, diluent used, date prepared, batch number and researcher initials.
Place the reconstituted solution into the required storage condition as soon as possible. Avoid unnecessary warming, cooling or repeated freeze-thaw cycles.
Some lyophilised peptide products may take time to fully hydrate. Dissolution should always be handled gently and according to laboratory protocol.
| Issue | What It May Indicate | Safer Response |
| Powder clinging to vial wall | Static or lyophilisation residue | Allow more contact time with diluent |
| Small particles remain | Incomplete hydration | Continue gentle swirling |
| Cloudy solution | Possible incompatibility or contamination | Stop and check documentation |
| Foaming | Too much agitation | Let the solution settle and avoid shaking |
| Colour change | Possible degradation or contamination | Do not continue without supplier guidance |
| Product identity unclear | Possible peptide mix-up or mislabelled product | Stop and confirm CoA before using |
| Storage Factor | Guidance |
| Product form | Lyophilised powder |
| Storage condition | Follow supplier label and Certificate of Analysis |
| Light exposure | Protect from unnecessary light exposure |
| Moisture exposure | Keep sealed until use |
| Temperature changes | Avoid repeated temperature cycling |
| Handling | Minimise unnecessary opening or vial puncture |
| Variant control | Store and label separately from Tirzepatide, Semaglutide, Cagrilintide and other metabolic research products |
| Storage Factor | Guidance |
| Storage condition | Follow validated research protocol |
| Labelling | Record product name, concentration, date, diluent and batch number |
| Freeze-thaw cycles | Avoid repeated freeze-thaw exposure |
| Aliquoting | Use small research aliquots where appropriate |
| Contamination control | Use clean laboratory technique |
| Light exposure | Protect from unnecessary light exposure where required |
| Disposal | Dispose according to laboratory waste procedures |
Peptides may be sensitive to temperature, light, pH, agitation and contamination. Storage conditions should be confirmed through supplier documentation or the laboratory’s validated method.
This page does not provide human dosing, injection instructions, dose escalation schedules, injection schedules, administration guidance or treatment guidance.
Retatrutide 10mg is not supplied for human or animal administration. It is a laboratory research-use product only.
For research settings, any measured aliquots should be prepared according to the concentration required by the approved research protocol. All calculations should be checked, documented and traceable.
| Planning Item | What to Record |
| Final concentration | Total peptide amount and diluent volume |
| Working solution | Concentration used in the research protocol |
| Aliquot volume | Volume transferred into each labelled lab tube |
| Batch details | Product batch, CoA and preparation date |
| Peptide identity | Confirmation that the product is Retatrutide / LY3437943 |
| Salt form | Supplier-specific salt form or counter-ion, where documented |
| Storage location | Fridge, freezer or other controlled storage area |
| Handler details | Researcher name or initials |
| Preparation date | Date and time of reconstitution |
| Disposal date | When the aliquot should no longer be used |
| Strength check | Confirmation that the 10mg vial strength matches the approved research protocol |
| Compliance check | Confirmation that no human-use, weight loss or injection wording is attached to the material |
Correct handling is important for research consistency, contamination control and product traceability. Most mistakes occur when products are not labelled clearly, concentration calculations are not recorded, storage conditions are not followed or consumer weight-loss claims are mixed into research-use product pages.
Because Retatrutide is commonly discussed online in relation to weight loss, fat loss and body transformation, product pages should avoid wording that could be interpreted as encouraging human self-use, injection, dose escalation or treatment use.
The recent Victorian health alert makes this especially important. Products labelled as Retatrutide, Reta, R-10 and R-20 have been linked to acute liver injury cases in Victoria, and investigations are ongoing.
| Always | Why It Matters |
| Check the Certificate of Analysis | Confirms batch-level information |
| Confirm peptide identity | Helps verify the product is Retatrutide / LY3437943 |
| Confirm salt form where documented | Supports correct research calculations |
| Use PPE | Reduces contamination and exposure risk |
| Label every vial and aliquot | Prevents mix-ups |
| Record concentration calculations | Supports traceability |
| Use clean laboratory technique | Reduces contamination risk |
| Follow institutional protocols | Keeps handling consistent and auditable |
| Store according to documentation | Helps protect peptide integrity |
| Dispose of lab waste correctly | Supports safety and compliance |
| Use research-use wording only | Reduces misleading human-use interpretation |
| Clearly separate research pathways from human benefit claims | Avoids unsafe or misleading product positioning |
| Include Australian compliance warnings where appropriate | Reduces risk around unapproved peptide promotion |
| Never | Why It Is Risky |
| Never use for self-injection | Product is research use only |
| Never sell or promote as a weight loss product | Creates human-use and compliance risk |
| Never make fat loss or body transformation claims | Not an approved or appropriate product claim |
| Never make obesity or diabetes treatment claims | Not suitable for a research-use product page |
| Never provide dose escalation guidance | Could be misused as treatment instruction |
| Never compare it as “stronger than Ozempic” in consumer wording | Creates unsafe and misleading therapeutic positioning |
| Never imply it is equivalent to approved GLP-1 medicines | Research products are not registered medicines |
| Never copy clinical trial dosing into product copy | Clinical protocols are not product-use instructions |
| Never assume purity without CoA | Batch quality must be documented |
| Never use a damaged or unlabelled vial | Identity and sterility may be uncertain |
| Never shake aggressively | May affect peptide integrity |
| Never use random solvents | May damage the peptide or alter research results |
| Never leave reconstituted product unlabelled | Creates traceability risk |
| Never rely on social media protocols | They may be inaccurate, unsafe or non-compliant |
The table below is for concentration planning only. It does not represent dosage, injection quantity, treatment quantity or recommended administration.
| Total Vial Amount | Diluent Volume | Final Concentration |
| 10mg | 1mL | 10mg/mL |
| 10mg | 2mL | 5mg/mL |
| 10mg | 2.5mL | 4mg/mL |
| 10mg | 4mL | 2.5mg/mL |
| 10mg | 5mL | 2mg/mL |
| 10mg | 10mL | 1mg/mL |
| 10mg | 20mL | 0.5mg/mL |
If a researcher adds 2mL of suitable research-grade diluent to a 10mg vial, the resulting concentration is 5mg/mL.
This calculation is for research concentration planning only. It is not a human or animal dosing example, treatment example, injection example or dose-escalation instruction.
Retatrutide, also known as LY3437943, is an investigational synthetic peptide studied in relation to GIP, GLP-1 and glucagon receptor pathway research. It is commonly described in research literature as a triple hormone receptor agonist.
Retatrutide is not only a GLP-1 receptor pathway compound. It is studied as a triple receptor agonist involving GIP, GLP-1 and glucagon receptor pathways.
No. Tirzepatide is commonly discussed as a dual GIP and GLP-1 receptor agonist. Retatrutide is studied as a triple GIP, GLP-1 and glucagon receptor agonist.
This research product is not approved or supplied for weight loss, fat loss, obesity, diabetes, appetite control, body transformation or human administration. It should be described only as a laboratory research product.
Australian health authorities have recently raised concerns about unapproved peptide products, including retatrutide. The Victorian Department of Health reported acute liver injury cases linked to products labelled Retatrutide, Reta, R-10 or R-20, and the TGA has separately warned about serious adverse effects associated with unapproved peptides.
No. Semaglutide is a GLP-1 receptor agonist medicine/research context, while Retatrutide is studied as a triple GIP, GLP-1 and glucagon receptor agonist.
No. Retatrutide is a triple incretin receptor agonist research peptide. Cagrilintide is an amylin analogue research peptide. They belong to different research classes.
A Certificate of Analysis provides batch-level testing information. It helps researchers verify product identity, purity, salt form, sequence and quality documentation before use in a research setting.
| Resource | Why It Is Useful |
| PubChem Retatrutide compound profile | Useful background on Retatrutide identity and compound information. |
| New England Journal of Medicine Retatrutide phase 2 trial | Useful clinical research context on Retatrutide as a triple hormone receptor agonist. This should not be used as a product-use claim for research vials. |
Research Use Only: Retatrutide 10mg is supplied strictly for laboratory research purposes. It is not intended for human or animal consumption, injection, therapeutic use, cosmetic use, diagnostic use, weight loss, fat loss, obesity treatment, diabetes management, appetite control, insulin sensitivity, metabolic treatment, anti-ageing, bodybuilding, body transformation or performance enhancement. Information on this page is provided for research education and product handling context only. Always follow applicable laws, institutional procedures, supplier documentation, SDS guidance and qualified laboratory protocols.
Find research peptides, certificate documentation, guides and key product categories in one clean menu.